352 related articles for article (PubMed ID: 11561092)
1. SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates.
Bontempi B; Whelan KT; Risbrough VB; Rao TS; Buccafusco JJ; Lloyd GK; Menzaghi F
J Pharmacol Exp Ther; 2001 Oct; 299(1):297-306. PubMed ID: 11561092
[TBL] [Abstract][Full Text] [Related]
2. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors.
Bontempi B; Whelan KT; Risbrough VB; Lloyd GK; Menzaghi F
Neuropsychopharmacology; 2003 Jul; 28(7):1235-46. PubMed ID: 12700710
[TBL] [Abstract][Full Text] [Related]
3. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Schneider JS; Tinker JP; Menzaghi F; Lloyd GK
J Pharmacol Exp Ther; 2003 Jul; 306(1):401-6. PubMed ID: 12721323
[TBL] [Abstract][Full Text] [Related]
4. Effects of (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys.
Terry AV; Risbrough VB; Buccafusco JJ; Menzaghi F
J Pharmacol Exp Ther; 2002 Apr; 301(1):284-92. PubMed ID: 11907185
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a nicotinic acetylcholine receptor ligand.
Rao TS; Adams PB; Correa LD; Santori EM; Sacaan AI; Reid RT; Suto CM; Vernier JM
Brain Res; 2003 Aug; 981(1-2):85-98. PubMed ID: 12885429
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thiophenol hydrochloride (SIB-1553A), a novel cholinergic ligand: microdialysis studies.
Rao TS; Reid RT; Correa LD; Santori EM; Gardner MF; Sacaan AI; Lorrain D; Vernier JM
Brain Res; 2003 Oct; 986(1-2):71-81. PubMed ID: 12965231
[TBL] [Abstract][Full Text] [Related]
7. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.
Schneider JS; Tinker JP; Van Velson M; Menzaghi F; Lloyd GK
J Pharmacol Exp Ther; 1999 Aug; 290(2):731-9. PubMed ID: 10411585
[TBL] [Abstract][Full Text] [Related]
8. Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys.
Decamp E; Schneider JS
Eur J Neurosci; 2006 Oct; 24(7):2098-104. PubMed ID: 17067307
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist.
Rao TS; Adams PB; Correa LD; Santori EM; Sacaan AI; Reid RT; Cosford ND
Brain Res; 2008 Oct; 1234():16-24. PubMed ID: 18692487
[TBL] [Abstract][Full Text] [Related]
10. 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors.
Vernier JM; El-Abdellaoui H; Holsenback H; Cosford ND; Bleicher L; Barker G; Bontempi B; Chavez-Noriega L; Menzaghi F; Rao TS; Reid R; Sacaan AI; Suto C; Washburn M; Lloyd GK; McDonald IA
J Med Chem; 1999 May; 42(10):1684-6. PubMed ID: 10346920
[No Abstract] [Full Text] [Related]
11. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys.
Decker MW; Bannon AW; Curzon P; Gunther KL; Brioni JD; Holladay MW; Lin NH; Li Y; Daanen JF; Buccafusco JJ; Prendergast MA; Jackson WJ; Arneric SP
J Pharmacol Exp Ther; 1997 Oct; 283(1):247-58. PubMed ID: 9336330
[TBL] [Abstract][Full Text] [Related]
12. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys.
Buccafusco JJ; Terry AV; Decker MW; Gopalakrishnan M
Biochem Pharmacol; 2007 Oct; 74(8):1202-11. PubMed ID: 17706609
[TBL] [Abstract][Full Text] [Related]
13. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
[TBL] [Abstract][Full Text] [Related]
14. A study of the nicotinic agonist SIB-1553A on locomotion and attention as measured by the five-choice serial reaction time task.
Grottick AJ; Wyler R; Higgins GA
Pharmacol Biochem Behav; 2001 Dec; 70(4):505-13. PubMed ID: 11796150
[TBL] [Abstract][Full Text] [Related]
15. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model.
Decamp E; Schneider JS
Brain Res; 2009 Mar; 1262():109-14. PubMed ID: 19368843
[TBL] [Abstract][Full Text] [Related]
16. Nicotinic receptor subtypes and cognitive function.
Levin ED
J Neurobiol; 2002 Dec; 53(4):633-40. PubMed ID: 12436426
[TBL] [Abstract][Full Text] [Related]
17. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
Decker MW; Brioni JD; Sullivan JP; Buckley MJ; Radek RJ; Raszkiewicz JL; Kang CH; Kim DJ; Giardina WJ; Wasicak JT
J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
[TBL] [Abstract][Full Text] [Related]
18. Ultra-low exposure to α-7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in α-7 receptor expression in rodents: implications for low dose clinical efficacy.
Werkheiser JL; Sydserff S; Hubbs SJ; Ding M; Eisman MS; Perry D; Williams AJ; Smith JS; Mrzljak L; Maier DL
Neuroscience; 2011 Jul; 186():76-87. PubMed ID: 21550383
[TBL] [Abstract][Full Text] [Related]
19. Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys.
Terry AV; Plagenhoef M; Callahan PM
Psychopharmacology (Berl); 2016 Mar; 233(5):761-71. PubMed ID: 26612616
[TBL] [Abstract][Full Text] [Related]
20. Strain-dependent effects of cognitive enhancers in the mouse.
Sunyer B; Patil S; Frischer C; Hoeger H; Lubec G
Amino Acids; 2008 Apr; 34(3):485-95. PubMed ID: 17690951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
